34 completed, 15 unknown, 4 active not recruiting, 2 terminated. 57 Phase 3, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 57 | Completed 34, Unknown 15, Active not recruiting 4, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 15 | Unknown 6, Completed 4, Active not recruiting 2, Terminated 2, Withdrawn 1 |
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 1054 | 2025-04-16 | 2026-10-30 |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema BAT5906 injection, Lucentis - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Bio-Thera Solutions | 406 | 2024-10-09 | 2026-04-07 |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 984 | 2024-08-07 | 2026-11-10 |
| A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Ranibizumab 10mg/ml Injection, Lucentis - Diabetic Macular Edema, Diabetic Retinopathy | Phase 3 | Completed | Incepta Pharmaceuticals Ltd | 70 | 2024-03-30 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | Hoffmann-La Roche | 280 | 2024-03-06 | 2026-07-31 |
| A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss 601 1.25mg, ranibizumab 0.5mg - Branch Retinal Vein Occlusion | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 351 | 2022-12-27 | 2025-12-18 |
| Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) Bevacizumab, Ranibizumab Ophthalmic - Wet Age-related Macular Degeneration | Phase 3 | Completed | Parc de Salut Mar | 172 | 2022-11-18 | 2026-11-10 |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration BAT5906 injection, Lucentis - Neovascular (Wet) Age-related Macular Degeneration | Phase 3 | Completed | Bio-Thera Solutions | 488 | 2022-07-07 | 2025-12-08 |
| TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration TAB014 Monoclonal Antibody Injection, Ranibizumab Injection [Lucentis] - Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | BioDlink Biopharm Co., Ltd. | 488 | 2022-06-28 | 2025-01-07 |
| Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation Ranibizumab Injection [Lucentis], Inner limiting membrane stripping, Dexamethasone intravitreal implant - Diabetic Retinopathy | Phase 3 | Unknown | Affiliated Hospital of Nantong University | 60 | 2021-11-15 | 2023-08-01 |
| Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis - Age Related Macular Degeneration | Phase 3 | Completed | Shanghai Henlius Biotech | 407 | 2021-11-01 | 2025-03-24 |
| A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD MW02, Lucentis - Wet Age-related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 433 | 2021-05-07 | 2022-03-28 |
| Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity Ranibizumab (0.25 mg/0.025 mL) - Retina Disease, Retinopathy of Prematurity | Phase 3 | Completed | Zagazig University | 30 | 2020-11-20 | 2023-01-30 |
| Combination of Ranibizumab and Targeted Laser Photocoagulation Ranibizumab Injection, Laser photocoagulation - Central Retinal Vein Occlusion With Macular Edema | Phase 3 | Active not recruiting | University of Giessen | 88 | 2020-08-25 | 2026-05-08 |
| Combined Ranibizumab and Iluvien for Diabetic Macular Oedema Iluvien 0.19 MG Drug Implant, Ranibizumab Injection [Lucentis], Sham Intravitreal Injection - Diabetic Macular Edema, Diabetes | Phase 2 / Phase 3 | Withdrawn | Imperial College London | 2019-09-01 | 2023-10-02 | |
| Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery Lucentis - Diabetic Macular Edema, Cataract | Phase 3 | Unknown | Second Military Medical University | 90 | 2019-08-22 | 2020-03-26 |
| Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR) Ranibizumab, No drug - Diabetic Retinopathy, Ranibizumab | Phase 3 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 118 | 2018-04-01 | 2018-03-02 |
| Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg - Uveitis, Macular Edema | Phase 3 | Completed | JHSPH Center for Clinical Trials | 194 | 2017-03-09 | 2023-07-10 |
| Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Intravitreal ranibizumab - Glaucoma, Neovascular, Ranibizumab | Phase 3 | Unknown | LEANDRO CABRAL ZACHARIAS | 28 | 2016-10-01 | 2016-09-27 |
| Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab - Age-related Macular Degeneration | Phase 3 | Unknown | Ohr Pharmaceutical Inc. | 230 | 2016-04-12 | 2017-04-27 |
Showing 20 of 57. Sign in to see all of them.
Macular Degeneration (19) · Macular Edema (14) · Choroidal Neovascularization (8) · Retinal Vein Occlusion (7) · Diabetes Mellitus (5) · Vision Disorders (5) · Diabetic Retinopathy (4) · Edema (3) · Glaucoma (2) · Retinal Diseases (2) · Cataract (1) · Eales disease (1) · Glaucoma, Neovascular (1) · Hemorrhage (1) · Pterygium (1)
Genentech, Inc. (6) · Novartis Pharmaceuticals (5) · Bio-Thera Solutions (2) · EyeBiotech Ltd. (2) · JUNYAN ZHANG (2) · Novartis (2) · The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Affiliated Hospital of Nantong University (1) · Anders Kvanta (1) · BioDlink Biopharm Co., Ltd. (1) · Charles C Wykoff, PhD, MD (1) · East Florida Eye Institute (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1)
United States (17) · China (15) · Spain (7) · Austria (6) · Germany (6) · United Kingdom (6) · Australia (5) · Canada (5) · France (5) · Italy (5) · Switzerland (5) · Hungary (4) · India (4) · Netherlands (4) · Poland (4)
Charles Miller, MD PhD (2) · Jason Ehrlich, M.D., Ph.D. (2) · Reinier O Schlingemann, MD, PhD (2) · Roman Rubio, M.D. (2) · Abdhish Bhavsar, MD (1) · Adam R. Glassman, MS (1) · Anders Kvanta (1) · Avner Ingerman, MD (1) · Charles C Wykoff, PhD, MD (1) · Christina J. Flaxel, MD (1) · Dan Zhu, Doctor (1) · Daniel F Martin, MD (1)
PMID 32374423, PMID 34934034, PMID 22965590, PMID 23415775, PMID 23699977, PMID 23706949, PMID 24768239, PMID 25148789, PMID 26050541, PMID 26452713, PMID 26584450, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30419298, PMID 31047350, PMID 31047503, PMID 31668888, PMID 36774994, PMID 37585454, PMID 39680390, PMID 15564755, PMID 17367957, PMID 17804919, PMID 18214740, PMID 20332654, PMID 20417925, PMID 20572497, PMID 20856107, PMID 20885313, PMID 21526923, PMID 21681707, PMID 21860693, PMID 21915047, PMID 21955635, PMID 22081150, PMID 22150050, PMID 22241923, PMID 22357391, PMID 22424834, PMID 22444829, PMID 22452699, PMID 22512984, PMID 22555112, PMID 22737347, PMID 22737351, PMID 22848140, PMID 22882007, PMID 22939114, PMID 23047002
2019 (1), 2023 (1), 2025 (1), U10EY014231 (1), U10EY017823 (1), U10EY018817 (1), U10EY024527 (1)